Assertio Holdings, Inc. 8-K

What Happened Assertio Holdings, Inc. (ASRT) filed an 8-K on April 21, 2026, disclosing that, pursuant to a Merger Agreement dated April 8, 2026, Garda Therapeutics, Inc. and its wholly owned subsidiary Audi Merger Sub, Inc. intend to commence a tender offer to purchase all outstanding shares of Assertio common stock on April 29, 2026. The April 29 start date follows the expiration of the 20‑day “window‑shop” period described in the Merger Agreement. A company press release announcing the plan was attached to the filing as Exhibit 99.1.

Key Details

• 8-K filed: April 21, 2026.
• Merger Agreement date: April 8, 2026 (parties: Assertio, Garda Therapeutics, Audi Merger Sub).
• Tender offer commencement: April 29, 2026 — to purchase all outstanding Assertio common stock.
• Press release announcing the tender offer is included as Exhibit 99.1 to the 8-K.

Why It Matters This tender offer is a formal, public step in the acquisition process under the Merger Agreement and signals a potential change of control for Assertio. For shareholders, the tender offer will provide the opportunity to sell shares directly to the bidder once the offer materials are released; those materials will include the offer price, terms, and deadlines. Investors should review the press release and watch for the official tender offer documents and any additional proxy or regulatory filings for details before making decisions.